Summary
Dr Lal Path Labs shares surged nearly 8% to a new 52-week high after the company reported better-than-expected Q1 FY27 earnings, with consolidated net profit increasing 28% year-on-year to Rs 169.5 crore. Brokerages like Nomura, Nuvama, and JM Financial have maintained 'Buy' ratings and raised target prices, citing strong revenue growth and strategic investments.